Worldwide Organ on a Chip Report to 2035 - Industry Trends and Forecasts

DUBLIN, Nov. 2, 2022 /PRNewswire/ -- The "Organ on a Chip Market - Focus on Products and Technologies - Distribution by Type of Product based Models and Disease based Models), Application Area, Purpose, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to  ResearchAndMarkets.com's offering.

This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of organ-on-chip products and technologies, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

It is a well-known fact that almost 90% of the therapeutic interventions fail in clinical trials, resulting in significant economic losses to the pharmaceutical industry. The lack of effective preclinical prediction of drug responses in humans is one of the various reasons for drug's failure to get approved. Animal testing for preclinical evaluation of drugs sometimes fails to identify toxicity signs caused by a drug in humans.

Moreover, these studies are quite expensive, time-consuming and are associated with several ethical concerns. In order to reform the drug approval process and use non-animal testing models for preclinical evaluations, the US democrats and republicans introduced the FDA Modernization Act in 2021. The U.S. Environmental Protection Agency (EPA) has also declared the termination of the funds granted for the studies on mammals by 2035.

As a result, several stakeholders have opted to modernize their conventional testing methods in order to cope up with the increasing limitations associated with animal models. One such innovative technology, 'organ on a chip' has the potential to transform the drug discovery process by simulating the human physiological and functional environment on a microfluidic system.

The use of such novel testing models in drug discovery and toxicity testing has been steadily increasing. Up till now, several pharmaceutical manufacturers and research institutions have embraced the use of these in vivo like in vitro models; however, a remarkable rise in the adoption rate of these models has been observed since the FDA changed its laws towards putting an end on the animal testing models.

The novel organ on a chip models have various advantages over the traditional animal-based models, including fine control over microenvironment, lower cost, lesser time, easy to use and portable. Given the inherent benefits of organ on a chip technology, a number of players have launched their proprietary products in order to expedite preclinical studies of novel drug interventions across a wide array of disease indications. There are several organ on a chip models, including lung-on-chip, liver-on-chip, heart-on-chip, brain-on-chip and multiple organ models, which are being offered by various players.

Apart from offering efficient user-friendly organ-on-chip models, some developers also offer customization of these models as per the client requests. It is worth mentioning that various developers have made significant efforts in developing organ on chip technologies, paving the way for new innovations, primarily integrating artificial intelligence driven technology for early detection of pharmaceuticals and toxicity risks, along with detection of unknown mutations.

Driven by promising benefits over animal testing, increasing R&D activity and financial support from investors, the organ on a chip market is anticipated to grow at a commendable pace in the mid to long term.

Key Questions Answered

• Who are the leading players engaged in the development of organ-on-chip products and technologies?
• What are the different application areas where organ on a chip can be used?
• Primarily in which geographical regions, are the organ on a chip developers located?
• How has the intellectual property landscape of organ on a chip, evolved over the years?
• Which partnership models are commonly adopted by stakeholders in the organ on a chip domain?
• What are the investment trends and who are the key investors actively engaged in the research and development of organ on a chip systems?
• How is the current and future opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. ORGAN-ON-CHIP: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Organ-on-Chip: List of Products
4.2.1. Analysis by Type of Offering(s)
4.2.2. Analysis by Status of Development
4.2.3. Analysis by Type of Technology / Platform
4.2.4. Analysis by Number of Chips in a Plate
4.2.5. Analysis by Material Used for Construction of Chip / Plate
4.2.6. Analysis by Type of Polymer
4.2.7. Analysis by Compatible Tissue / Organ
4.2.8. Analysis by Application Area(s)
4.3. Organ-on-Chip: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Developers: Analysis by Number of Organ-on-Chip Products

5. ORGAN-ON-CHIP DEVELOPERS: COMPANY PROFILES
5.1. Chapter Overview
5.2. BEOnChip
5.2.1. Company Overview
5.2.2. Product Portfolio
5.2.3. Recent Developments and Future Outlook
5.3. Dynamic42
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.3. Recent Developments and Future Outlook
5.4. Emulate
5.4.1. Company Overview
5.4.2. Product Portfolio
5.4.3. Recent Developments and Future Outlook
5.5. Mimetas
5.5.1. Company Overview
5.5.2. Product Portfolio
5.5.3. Recent Developments and Future Outlook
5.6. SynVivo
5.6.1. Company Overview
5.6.2. Product Portfolio
5.6.3. Recent Developments and Future Outlook
5.7 TissUse
5.7.1. Company Overview
5.7.2. Product Portfolio
5.7.3. Recent Developments and Future Outlook
5.8 uFluidix
5.8.1. Company Overview
5.8.2. Product Portfolio
5.8.3. Recent Developments and Future Outlook

6. PATENT ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Organ-on-Chip: Patent Analysis
6.3.1. Analysis by Type of Patent
6.3.2. Analysis by Publication Year
6.3.3. Analysis by Annual Granted Patents
6.3.4. Analysis by Annual Patent Application
6.3.5. Analysis by Annual Granted Patents and Patent Application
6.3.6. Analysis by Location of Headquarters
6.3.7. Analysis by Type of Applicant
6.3.8. Analysis by Patent Age
6.3.9. Analysis by Geographical Region
6.3.10. Analysis by CPC Symbols
6.3.11. Leading Industry Players: Analysis by Number of Patents
6.3.12. Leading Non-Industry Players: Analysis by Number of Patents
6.3.13 Leading Inventors: Analysis by Number of Patents
6.4. Patent Benchmarking Analysis
6.4.1. Analysis by Patent Characteristics
6.5. Analysis by Patent Valuation

7. BRAND POSITIONING MATRIX
7.1. Chapter Overview
7.2 Methodology
7.3. Key Parameters
7.4. Companies Providing Organ-on-Chip
7.4.1. Brand Positioning Matrix: BiomimX
7.4.2. Brand Positioning Matrix: Emulate
7.4.3. Brand Positioning Matrix: NETRI
7.4.4. Brand Positioning Matrix: SynVivo
7.4.5. Brand Positioning Matrix: TissUSe
7.4.6. Brand Positioning Matrix: uFluidix

8. ACADEMIC GRANTS ANALYSIS
8.1 Chapter Overview
8.2. Scope and Methodology
8.3. Organ-on-Chip: Academic Grants Analysis
8.3.1. Analysis by Year of Grant Award
8.3.2. Analysis by Grant Amount Awarded
8.3.3. Analysis by Administering Institute Center
8.3.4. Analysis by Support Period
8.3.5. Analysis by Administering Institute Center and Support Period
8.3.6. Analysis by Administering Institute Center and Amount Awarded (USD Million)
8.3.7. Analysis by Type of Grant Application
8.3.8. Analysis by Purpose of Grant
8.3.9. Analysis by Activity Code
8.3.10. Word Cloud Analysis: Emerging Focus Area
8.3.11. Analysis by Study Section Involved
8.3.12. Popular NIH Departments: Analysis by Number of Grants
8.3.13. Analysis by Type of Recipient Organization
8.3.14. Analysis by Support Period and Amount Awarded
8.3.15. Popular Recipient Organizations: Analysis by Number of Grants
8.3.16. Popular Recipient Organizations: Analysis by Amount Awarded
8.3.17. Popular Recipient Organizations: Analysis by Geographical Location

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Organ-on-Chip: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Most Active Players: Analysis by Number of Partnerships
9.3.4. Analysis by Geographical Region
9.3.4.1 Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Organ-on-Chip: List of Funding and Investments
10.2.1. Analysis by Annual Instances
10.2.2. Analysis by Amount Invested per Year
10.2.3. Analysis by Type of Funding
10.2.4. Analysis by Type of Funding and Year of Establishment
10.2.5. Analysis by Type of Funding and Amount Invested
10.2.6. Analysis of Amount Invested by Geographical Region
10.2.7. Analysis by Purpose of Funding
10.2.8. Analysis by Associated Organ / System
10.2.9. Analysis by Therapeutic Area
10.2.10. Most Prominent Investors: Analysis by Number of Instances
10.2.11. Most Active Players: Analysis by Number of Funding Instances
10.2.12. Most Active Players: Analysis by Amount Raised
10.2.13. Summary of Investments

11. CASE STUDY: SCAFFOLD-FREE 3D CELL CULTURE SYSTEMS
11.1. Chapter Overview
11.2. Scaffold-free Products: Market Landscape
11.2.1. Analysis by Status of Development
11.2.2. Analysis by Type of Product
11.2.3. Analysis by Source of 3D Cultured Cells
11.2.4. Analysis by Method Used for Fabrication
11.2.5. Analysis by Material Used for Fabrication
11.2.6. Analysis by Type of Product and Source of 3D Cultured Cells
11.2.7. Analysis by Type of Product and Method Used for Fabrication
11.3. Scaffold Free Products: Developer Landscape
11.3.1. Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3. Analysis by Location of Headquarters
11.4. Leading Developers: Analysis by Number of Scaffold Free Products
11.5. Tree Map Representation: Analysis by Type of Product and Company Size

12. ORGAN-ON-CHIP: MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Organ-on-Chip Market, 2022-2035
12.3.1. Global Organ-on-Chip Market, 2022-2035: Distribution by Type of Product
12.3.1.1. Organ-on-Chip Market for Organ(s) based Models, 2022-2035
12.3.1.2. Organ-on-Chip Market for Disease(s) based Models, 2022-2035
12.3.2. Global Organ-on-Chip Market, 2022-2035: Distribution by Application Area
12.3.2.1. Organ-on-Chip Market for Cancer Research, 2022-2035
12.3.2.2. Organ-on-Chip Market for Drug Discovery and Toxicity Testing, 2022-2035
12.3.2.3. Organ-on-Chip Market for Stem Cell Research, 2022-2035
12.3.2.4. Organ-on-Chip Market for Tissue Engineering and Regenerative Medicine, 2022-2035
12.3.3. Global Organ-on-Chip Market, 2022-2035: Distribution by Purpose
12.3.3.1. Organ-on-Chip Market for Research Purposes, 2022-2035
12.3.3.2. Organ-on-Chip Market for Therapy Development, 2022-2035
12.3.4. Global Organ-on-Chip Market, 2022-2035: Distribution by Key Geographical Regions
12.3.4.1. Organ-on-Chip Market in North America, 2022-2035
12.3.4.2. Organ-on-Chip Market in Europe, 2022-2035
12.3.4.3. Organ-on-Chip Market in Asia-Pacific, 2022-2035
12.3.4.4. Organ-on-Chip Market in Rest of the World, 2022-2035

13. CONCLUSION

14. EXECUTIVE INSIGHTS

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/7g0zry

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets